Storys zum Thema Hearing loss

Bundesinnung der Hörakustiker KdöR

International health professionals: Campus Hearing Acoustic promotes global knowledge exchange

Acousia Therapeutics GmbH

Promising First-in-Patient Results for ACOU085 (INN: Bimokalner) in Cisplatin-Induced Ototoxicity

Tübingen (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company pioneering treatments for acute and chronic inner ear hearing loss, today announced positive top-line efficacy results from its completed Phase 2a PROHEAR Study. ACOU085 is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across ...

Acousia Therapeutics GmbH

Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity

Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small ...

Bosch Healthcare Solutions GmbH

Vivalytic Bacterial Meningitis by Bosch: PCR rapid test for medical emergencies

Technische Universität München

Research towards improved cochlear implants

TECHNICAL UNIVERSITY OF MUNICH Corporate Communications Center phone: +49 89 289 10808 - e-mail: presse@tum.de - web: www.tum.de This text on the web: https://www.tum.de/nc/en/about-tum/news/press-releases/details/35937/ High resolution images: https://mediatum.ub.tum.de/1540122 NEWS RELEASE Research towards improved cochlear implants Computer model shows neuronal activation patterns in the inner ear Cochlear implants ...